Found 486 results in Expert Content

Poorly soluble oral small molecules often face compounded development risks, including food effects, high dose requirements, variability in exposure, and the need for rapid onset.

Abstract: Pulmonary drug delivery is no longer limited to asthma and COPD. The field now spans hundreds of active programs, many led by emerging biotechs that must make early, high-impact decisions with limited data.

Abstract: Selling CDMO services is a complex task that calls for broad skill and technical depth.

Summary:​ Drug development today is shaped by 2 forces: the technical challenge of formulating complex molecules and the external challenge of navigating unstable global supply chains.

Catalent’s micronization services help innovators overcome the toughest drug development challenges.

A clinical-stage biotech focused on neurology faced challenges with a lipophilic, oxidation-sensitive molecule limited by solubility, stability, and scalability.

Vinorelbine, a chemotherapy agent traditionally given by IV infusion, was reformulated into the first approved oral softgel capsule through a collaboration between Pierre Fabre and Catalent.

Summary: Late-stage scaling of spray drying for inhaled formulations can result in avoidable delays, post-approval issues, and cost overruns.

Bringing complex oral drugs to the clinic requires overcoming significant solubility, permeability, and bioavailability challenges.

Summary: Pharmaceutical innovators face growing pressure to overcome solubility, permeability, and bioavailability challenges, especially for complex, poorly soluble molecules.